Orchestra Medical Ventures
Orchestra Medical Ventures (formerly Accelerated Technologies Partners) is an investment firm that employs a proprietary and innovative strategy to create, build and invest in medical technology companies intended to generate substantial clinical value and superior investor returns. Specifically, the Orchestra Strategy is based on coordinated collaboration with multi-disciplinary teams comprised of world-leading physicians and experienced technical and business experts. Working with these teams, Orchestra immerses itself into selected high-value, high-need clinical sectors in order to identify and analyze important unmet clinical needs that provide significant opportunities for technology innovations that can improve outcomes while reducing costs and complications. With these opportunities in mind, Orchestra and its sector-specific teams then work to conceive or source and then develop an optimal device solution to address such targeted unmet need. The Orchestra Strategy has been successfully pursued since 2000 through a predecessor medical device accelerator called Accelerated Technologies, Inc. ("ATI"), which continues to be operated by Orchestra. Orchestra's distinctive aproach is designed to significantly improve the likelihood of success of investing in medical technology innovation by aligning the interests and harnessing the collective talent of physicians, management and investors from inception through value creation and realization.
Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the U.S. and Israel, dedicated to improving endoscopy outcomes, lowering costs and enhancing patient experiences. The Company is focused on the development and commercialization of the Pure-Vu® System to improve the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon.
Mitralign is a venture backed privately held company located in a suburb of Boston, MA. The company is developing an innovative catheter based technology for percutaneous treatment of functional mitral regurgitation. The novel Mitralign system emulates surgical annuloplasty as it delivers a series of surgical implants directly into the mitral annulus by means of a catheter. The implants are cinched together, thus reducing the size of the mitral valve annulus and the valve opening. Mitralign is funded by top tier venture capitalists and has two major cardiovascular device companies as investors.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.